Tag Archives: After

NICE blames BioMarin for Brineura rejection after price talks break down

BioMarin and England’s cost-effectiveness gatekeeper have been negotiating for a year, but that hasn’t helped the rare-disease specialist secure reimbursement for its Batten disease drug Brineura. Friday, the National Institute for Health and Care Excellence (NICE) published draft guidance sticking with its earlier decision not to endorse Brineura in children with the disease, an inherited… Read More »

Pfizer Japan drawn into valsartan recall after finding API from Mylan is tainted

The global recall of valsartan has now extended to Pfizer and to Japan, via Mylan and India. According to a translated copy of its announcement, Pfizer’s Tokyo-based Japanese subsidiary said it is recalling from the country five lots of its blood pressure combo drug Amubaro because its API contains impurities that are probable carcinogens. The recall began… Read More »